TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22085872
Drug: Enalapril-FA tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril-FA tablet (10 mg enalapril combined with 0.4 mg of FA, low FA group)
Study: 19640950
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg anthocyanins twice daily for 12 weeks
Study: 15619106
Drug: 1.74% THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.74% THC (low dose)
Study: 15619106
Drug: 2.93% THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.93% THC (high dose)
Study: 9482769
Drug: Quercetin-containing supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin-containing supplement (1.0 g quercetin/d)
Study: 8023779
Drug: Fluvastatin, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin, 20 mg/day for 6 weeks
Study: 8023779
Drug: Fluvastatin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin + niacin (titrated to a maximum of 3 g/day for a further 9 weeks)
Study: 1097198
Drug: clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: clobetasol propionate cream 0.05%
Study: 24341333
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) group
Study: 20536470
Drug: Topically administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically administered Tbeta4 (0.03%)
Study: 17993603
Drug: beta‐adrenergic blockade‐intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta‐adrenergic blockade‐intravenous propranolol (0.2 mg/kg)
Study: 17993603
Drug: parasympathetic blockade‐intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: parasympathetic blockade‐intravenous atropine (0.04 mg/kg)
Study: 16368440
Drug: Intraperitoneal (IP)
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal (IP) chemotherapy (paclitaxel 135 mg/m² IV over 24 h, cisplatin 100 mg/m² IP day 2, paclitaxel 60 mg/m² IP day 8) every 21 days for six cycles
Study: 16368440
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) chemotherapy (alternate regimen for patients unable to receive IP therapy)
Study: 12744096
Drug: Rubber band
Normalized name: CLOSURE,RUBBER BAND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rubber band ligation + local anaesthetic injection (n = 70)
Study: 8421077
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg continuous sc GHRH 1-44 infusion daily for 14 days
Study: 8421077
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg continuous sc GHRH 1-44 infusion daily for 14 days
Study: 8043977
Drug: Control (baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (baseline measurements before treatment)
Study: 2684916
Drug: Reperfusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reperfusion therapy (thrombolysis or coronary angioplasty or both)
Study: 27852617
Drug: Long-chain n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-chain n-3 PUFA (3 g fish oil/d)
Study: 27852617
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 g safflower oil/d)
Study: 21467302
Drug: Continuous iv
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous iv infusion of combined GHRH/GHRP‐2 during pharmacological estradiol (E(2); women) or testosterone (T; men) supplementation
Study: 21467302
Drug: Continuous iv
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous iv infusion of combined GHRH/GHRP‐2
Study: 7557823
Drug: Modafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200 mg) every 8 hours for three days
Study: 1959004
Drug: Oxerutins (Paroven
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxerutins (Paroven 500 mg twice daily)
Study: 1959004
Drug: Both oxerutins
Normalized name: oxerutins
DrugBank: Oxerutins (DB15826)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oxerutins and placebo (compliance with tablets and stockings)
Study: 26573188
Drug: Entecavir (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir (0.5 mg/day, oral)
Study: 26573188
Drug: Adefovir (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir (10 mg/day, oral)
Study: 23102599
Drug: High titer
Normalized name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: High titer of IgG antibodies to malondialdehyde modified oxidized low-density lipoproteins (oxLDLAbs)
Study: 23102599
Drug: Low titer
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low titer of IgG antibodies to malondialdehyde modified oxidized low-density lipoproteins (oxLDLAbs)
Study: 19055285
Drug: Bilateral Yongquan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral Yongquan (KI 1) application with Biyankang Tablet, once each night
Study: 12591005
Drug: Borage oil
Normalized name: Borage oil
DrugBank: Borage oil (DB11238)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Borage oil 3000 mg daily
Study: 12591005
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil 3000 mg daily
Study: 12591005
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil 1500 mg and borage oil 1500 mg daily
Study: 11045840
Drug: Dietary counseling
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary counseling plus 628 +/- 254 mL of an energy supplement rich in fat (31% of energy) and linoleic acid (16% of energy) for 3 months
Study: 1462745
Drug: Selective intestinal
Normalized name: pork intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective intestinal decontamination (3 oral nonabsorbable antibiotics: Neomycin 1 gr, Colistin 1.500.000 U, Nystatin 1.000.000 U every 6 hours for first 74 patients; Norfloxacin 400 mg BID for following patients) for at least 5 days
Study: 6239538
Drug: Low-dose chlorozotocin
Normalized name: chlorozotocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose chlorozotocin (120 mg/m2 if untreated, 100 mg/m2 if treated)
Study: 6239538
Drug: High-dose chlorozotocin
Normalized name: chlorozotocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chlorozotocin (200 mg/m2 if untreated, 175 mg/m2 if treated)
Study: 6239538
Drug: Low-dose and
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose and high-dose chlorozotocin
Study: 6239538
Drug: High-dose chlorozotocin
Normalized name: chlorozotocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chlorozotocin
Study: 30187978
Drug: Varenicline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (0.5 mg for 1 week, then 1 mg for 11 weeks, twice daily)
Study: 30187978
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical unlabelled tablets for 12 weeks)
Study: 26242048
Drug: Qilin Pills
Normalized name: Qilib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qilin Pills (6 g, tid) combined with clomiphene (50 mg, qd)
Study: 26242048
Drug: Clomiphene (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene (50 mg, qd) alone
Study: 23482340
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (methotrexate injection alone)
Study: 23482340
Drug: Conservative surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative surgery with post-operative methotrexate injection
Study: 20586147
Drug: Polarized light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polarized light (PL) applied to neuropathic ulcers of diabetic foot twice daily for ten minutes for three months
Study: 20586147
Drug: Antioxidants (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants (60 mg hydrosoluble CoQ10, 100 mg alpha‐lipoic acid (ALA), and 200 mg vitamin E) used in two daily doses for three months
Study: 3979007
Drug: Terbutaline (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (0.075 mg/kg three times a day)
Study: 3979007
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline (10 mg/kg twice a day)
Study: 29708281
Drug: OBE022 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBE022 (single ascending doses of 10, 30, 100, 300, 1000 or 1300 mg; multiple ascending doses of 100, 300 or 1000 mg day-1 for 7 days)
Study: 24708640
Drug: N-acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (600 mg) and magnesium (200 mg)
Study: 12893153
Drug: Intra-articular Hyalgan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular Hyalgan injections
Study: 19276493
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg bolus dose followed by 75 mg once daily)
Study: 16822130
Drug: Sequential effects
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential effects in the Simon task
Study: 12738811
Drug: SC‐51 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC‐51 (200 mg)
Study: 15897698
Drug: Prulifloxacin 600
Normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prulifloxacin 600 mg once daily for 10 days
Study: 10023111
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg lysine-acetylsalicylic acid i.v.
Study: 10023111
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ergotamine s.c.
Study: 7478833
Drug: Dexamethasone phosphate
Normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone phosphate 0.6 mg/kg/d (dexamethasone base 0.5 mg/kg/d)
Study: 7049957
Drug: Erythromycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (2 X 1 g daily per os)
Study: 7049957
Drug: Amoxicillin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (3 X 0.75 g daily per os)
Study: 31134323
Drug: Oral vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vinorelbine (60 mg/m2)
Study: 31134323
Drug: Intravenous vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vinorelbine (25 mg/m2)
Study: 31134323
Drug: Population pharmacokinetic
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Population pharmacokinetic analysis (oral: n=222; intravenous: n=111)
Study: 31134323
Drug: Reference European
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference European data set (oral: 80 mg/m2; intravenous: 30 mg/m2)
Study: 22386472
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ABT-894 twice daily
Study: 22386472
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg ABT-894 twice daily
Study: 22386472
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ABT-894 twice daily
Study: 22386472
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg ABT-894 twice daily
Study: 22386472
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg duloxetine once per day (Study 1)
Study: 20201945
Drug: Pegylated Escherichia
Normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated Escherichia Coli Asparaginase (Peg‐ASP) 1000 units/m(2) with concurrent heparin prophylaxis
Study: 15569860
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 2 mg, vitamin B12 0.5 mg, and vitamin B6 25 mg
Study: 12101076
Drug: Early dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Early dexamethasone therapy
Study: 10189536
Drug: rhIGF‐I at
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I at a dose of 40/40 micrograms/kg
Study: 10189536
Drug: rhIGF‐I at
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I at a dose of 80/40 micrograms/kg
Study: 10189536
Drug: rhIGF‐I at
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I at a dose of 80/60 micrograms/kg
Study: 10189536
Drug: Intensified insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensified insulin therapy alone (placebo)
Study: 10189536
Drug: rhIGF‐I/insulin cotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I/insulin cotherapy
Study: 10189536
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of rhIGF‐I
Study: 2271083
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (low-dose azathioprine, cyclosporin, methylprednisolone) continued (group A)
Study: 27492741
Drug: Repetitive intracutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive intracutaneous injections with local anesthetics and steroids
Study: 21899566
Drug: 24% EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24% EDTA gel (30 min)
Study: 21899566
Drug: 2% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% CHX gel (30 min)
Study: 19014354
Drug: Desferroxamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desferroxamine infusion for 8 hours
Study: 19014354
Drug: Desferroxamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desferroxamine infusion
Study: 15343531
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia plus femoral nerve block (FNB) with 30 mL of 0.5% bupivacaine with epinephrine 1:200,000
Study: 15343531
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia plus femoral nerve block (FNB) with 30 mL of preservative-free saline
Study: 11451621
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE) 0.625 mg/day for 21 days followed by chlormadinone acetate for 5 days
Study: 9511844
Drug: Geriatric Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geriatric Oral Health Assessment Index (GOHAI)
Study: 9511844
Drug: Self-reported need
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported need for dental treatment
Study: 7872725
Drug: CA 19.9
Normalized name: CA 19.9 - Carbohydrate antigen 19.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA 19.9 > 37 U/ml
Study: 7872725
Drug: CEA >
Normalized name: Carcinoembryonic Antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEA > 5 ng/ml
Study: 27185699
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg (P150)
Study: 27185699
Drug: Pregabalin 75
Normalized name: pregabalin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 75 mg (P75)
Study: 27185699
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg (D5)
Study: 19531931
Drug: ProSorb-D 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProSorb-D 12.5 mg
Study: 19531931
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium 50 mg tablet
Study: 15967914
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate cream, 40-g/d dosage
Study: 15967914
Drug: Oral corticosteroids,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids, 0.5 or 1.0 mg/kg per day depending on extent of BP
Study: 1902410
Drug: ponalrestat (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: ponalrestat (two 300 mg tablets daily)
Study: 31189759
Drug: Lipid-modifying therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-modifying therapy (LT) level I with low HDL-C (＜40 mg/dL for men; ＜50 mg/dL for women)
Study: 31189759
Drug: Lipid-modifying therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-modifying therapy (LT) level II with high HDL-C (≥ 40 mg/dL for men; ≥ 50 mg/dL for women)
Study: 31189759
Drug: Lipid-modifying therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-modifying therapy (LT) level III with high HDL-C and low triglycerides (＜150 mg/dL)
Study: 31189759
Drug: No lipid-modifying
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No lipid-modifying therapy (LT) prescribed (level 0)
Study: 31189759
Drug: Lipid-modifying therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-modifying therapy (LT) level I
Study: 31189759
Drug: Lipid-modifying therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-modifying therapy (LT) level II
Study: 31189759
Drug: Lipid-modifying therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-modifying therapy (LT) level III
Study: 29088237
Drug: Current weekend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current weekend allied health service (including physical therapy, occupational therapy, speech therapy, dietetics, social work, and allied health assistant services)
Study: 15451336
Drug: Mifepristone and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone and misoprostol (misoprostol administered 6-8 hours vs. 23-25 hours after mifepristone)
Study: 11553119
Drug: Household cleansing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Household cleansing solutions adjusted to pH 7.4
Study: 11553119
Drug: Household cleansing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Household cleansing solutions adjusted to pH 10.0
Study: 11553119
Drug: Household cleansing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Household cleansing solutions adjusted to pH 10.8
Study: 8014642
Drug: Fixed low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fixed low-dose warfarin (2 mg/d)
Study: 8014642
Drug: Adjusted higher-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted higher-dose warfarin
Study: 2685260
Drug: Radiographic assessments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiographic assessments of implants
Study: 26481821
Drug: Ranibizumab 0.3
Normalized name: RANIBIZUMAB 0.3MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.3 mg monthly (frequent regimen; n = 102)
Study: 26481821
Drug: Ranibizumab 0.3
Normalized name: RANIBIZUMAB 0.3MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.3 or 0.5 mg quarterly (infrequent regimen; n = 217)
Study: 24344871
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of reading acceleration and WM training
Study: 22431170
Drug: Goserelin (GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (GnRH agonist)
Study: 22431170
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy (Bicalutamide and Goserelin)
Study: 15502600
Drug: d,l‐MPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: d,l‐MPH
Study: 9540946
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg linoleic acid and 600 mg calcium
Study: 9540946
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg starch and 600 mg lactose placebo
Study: 28679020
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg administered with food (evening meal for AF, morning meal for DVT)
Study: 28679020
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg administered with food
Study: 28679020
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg administered with evening meal (AF population)
Study: 28679020
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg administered with morning meal (DVT population)
Study: 25034935
Drug: S(+)‐ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine 0.5 mg.kg‐1 (S+K group)
Study: 25034935
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine 1.5 mg.kg‐1 (L5% group)
Study: 25034935
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline 3 ml (SF group; control group)
Study: 24151326
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of 25 to 30 minutes of aerobic exercise (STAN)
Study: 24151326
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of 50 to 60 minutes of aerobic exercise (HIGH)
Study: 24151326
Drug: Combined dose
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined dose of 50 to 60 minutes of aerobic and resistance exercise (COMB)
Study: 21218090
Drug: Ginger (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (1.2 g)
Study: 19388899
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg hyperbaric bupivacaine
Study: 19388899
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg hyperbaric bupivacaine with 15 microg of clonidine
Study: 14985138
Drug: 0.17 l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.17 l of water every 1/2 hour
Study: 14985138
Drug: 0.6 l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 l of water every 1/2 hour
Study: 7506174
Drug: nimesulide (50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: nimesulide (50mg twice daily)
Study: 18379535
Drug: Icodextrin solution
Normalized name: icodextrin Irrigation Solution
DrugBank: Icodextrin (DB00702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Icodextrin solution
Study: 27043667
Drug: 1.5% glucose-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% glucose-based biocompatible neutral pH solution